Form 4: Amneal Pharmaceuticals Executive Vice President Andrew Boyer Reports Stock Transactions
SEC Form 4 Filing
Executive Vice President Andrew Boyer reports transactions involving Amneal Pharmaceuticals Class A Common Stock, including acquisitions and disposals related to vesting of restricted stock units.
Summary
- Andrew Boyer, Executive Vice President of Amneal Pharmaceuticals, reported transactions involving the company's Class A Common Stock.
- On March 3, 2025, Boyer acquired shares through the vesting of restricted stock units and performance-based restricted stock units.
- Simultaneously, shares were disposed of to cover tax withholding obligations related to the vesting of these units.
- The transactions resulted in a net change in Boyer's beneficial ownership of Amneal Pharmaceuticals stock.
- On March 4, 2025, Boyer acquired additional shares through vesting of restricted stock units and disposed of shares to cover tax obligations.
Sentiment
Score: 6
Explanation: The document reflects routine transactions related to executive compensation. There are no indications of unusual or concerning activity. The sentiment is neutral.
Positives
- The vesting of restricted stock units and performance-based restricted stock units indicates that Boyer is receiving compensation tied to the company's performance.
- The vesting of performance-based restricted stock units suggests that the company has met certain performance thresholds.
Negatives
- The disposal of shares to cover tax withholding obligations reduces Boyer's overall stake in the company, although this is a common practice.
Risks
- The value of the restricted stock units is contingent on the price of Amneal Pharmaceuticals' Class A Common Stock.
- The performance-based restricted stock units are subject to the company achieving certain average closing prices per share over a three-year performance period, which may not be guaranteed.
Future Outlook
The document outlines future vesting schedules for restricted stock units and performance-based restricted stock units, indicating potential future equity compensation for the reporting person.
Industry Context
Form 4 filings are a standard part of regulatory compliance for corporate insiders, providing transparency into their trading activities and ownership positions. This filing indicates routine equity compensation and tax-related transactions, which are common in the pharmaceutical industry.
Comparison to Industry Standards
- Equity compensation is a common practice in the pharmaceutical industry to align the interests of executives with those of shareholders.
- Companies like Teva Pharmaceutical Industries and Mylan (now Viatris) also utilize restricted stock units and performance-based awards as part of their executive compensation packages.
- The vesting schedules and performance metrics associated with these awards are typically designed to incentivize long-term value creation.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in beneficial ownership, but the overall effect is likely to be negligible.
- Employees may be indirectly affected by the performance-based metrics associated with the restricted stock units, as these metrics can influence company strategy and operations.
Key Dates
| Date | Description |
|---|---|
| 03/03/2022 | Reporting person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. |
| 03/03/2022 | The reporting person was granted 157,005 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 03/03/2023 | The reporting person was granted 198,777 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 03/04/2024 | The Reporting Person was granted 152,778 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 03/03/2025 | Date of multiple transactions involving Class A Common Stock and Restricted Stock Units. |
| 03/04/2025 | Date of multiple transactions involving Class A Common Stock and Restricted Stock Units. |
| 03/05/2025 | Date of signature for the Form 4 filing. |
| 02/28/2028 | The last day of the performance period for performance-based restricted stock units granted on March 3, 2025. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.